Potentials of the current pharmacotherapy of endometriosis

Dumanovskaya M.R., Tabeeva G.I., Ivannikova Yu.A., Solopova A.E., Asaturova A.V., Smetnik A.A., Alieva P.M., Ermakova E.I., Pavlovich S.V.

1) Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, Moscow, Russia; 2) I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia, Moscow, Russia
Endometriosis is a chronic polyetiological disease characterized by the presence of endometrial-like tissue outside the uterine cavity. The known symptoms of endometriosis include the following: dysmenorrhea, dyspareunia, dysuria, dyschezia, chronic pelvic pain, and infertility. Postoperative endometriosis recurrences are known to occur in approximately 50% of patients within 5 years in the absence of postoperative suppressive treatment. The paper describes different groups of drugs (gonadotropin-releasing hormone agonists and antagonists, progestogens, combined hormonal contraceptives, dopamine agonists, and metformin) for the treatment of endometriosis, their mechanism of action, and their efficacy in relieving chronic pelvic pain, preventing endometriosis recurrences, side effects, and the impact on quality of life.
Conclusion: Taking into account the chronic nature of the disease, today it is important to find effective drugs with a minimum number of side effects, which will relieve pain syndrome and reduce the frequency of surgical re-interventions and endometriosis relapses.

Authors’ contributions: Dumanovskaya M.R., Ivannikova Yu.A., Tabeeva G.I. – concept and design; Dumanovskaya M.R., Tabeeva G.I., Ivannikova Yu.A., Solopova A.E. – writing the text; Pavlovich S.V., Asaturova A.V., Smetnik A.A., Alieva P.M., Ermakova E.I. – editing.
Conflicts of interest: The authors declare that there are no conflicts of interest.
Funding: The investigation has been conducted within the framework of State Assignment No. 122020900125-8.
For citation: Dumanovskaya M.R., Tabeeva G.I., Ivannikova Yu.A., Solopova A.E., Asaturova A.V., Smetnik A.A., Alieva P.M., Ermakova E.I., Pavlovich S.V. Potentials of the current pharmacotherapy of endometriosis.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2023; (2): 38-45 (in Russian)


treatment of endometriosis


  1. Zondervan K.T., Becker C.M., Missmer S.A. Endometriosis. N. Engl. J. Med. 2020; 382(13): 1244-56. https://dx.doi.org/10.1056/NEJMra1810764.
  2. Адамян Л.В., Кулаков В.И., Андреева Е.Н. Эндометриозы. Руководство для врачей. М.: Медицина; 1998. 380с. [Adamyan L.V., Kulakov V.I., Andreeva E.N. Endometriosis. Guidelines for physicians. Moscow: Medicine; 1998. 380p. (in Russian)].
  3. Gallagher J.S., DiVasta A.D., Vitonis A.F., Sarda V., Laufer M.R., Missmer S.A. The impact of endometriosis on quality of life in adolescents. J. Adolesc. Health. 2018; 63(6): 766-72. https://dx.doi.org/10.1016/j.jadohealth.2018.06.027.
  4. Nnoaham K.E., Hummelshoj L., Webster P., d'Hooghe T., de Cicco Nardone F., de Cicco Nardone C. et al. World Endometriosis Research Foundation Global Study of Women's Health consortium. Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertil. Steril. 2011; 96(2): 366-73.e8. https://dx.doi.org/10.1016/j.fertnstert.2011.05.090.
  5. Rush G., Misajon R., Hunter J.A., Gardner J., O'Brien K.S. The relationship between endometriosis-related pelvic pain and symptom frequency, and subjective wellbeing. Health Qual. Life Outcomes. 2019; 17(1): 123.https://dx.doi.org/10.1186/s12955-019-1185-y.
  6. Simoens S., Dunselman G., Dirksen C., Hummelshoj L., Bokor A., Brandes I. et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum. Reprod. 2012; 27(5): 1292-9. https://dx.doi.org/10.1093/humrep/des073.
  7. Shafrir A.L., Farland L.V., Shah D.K., Harris H.R., Kvaskoff M., Zondervan K. et al. Risk for and consequences of endometriosis: A critical epidemiologic review. Best Pract. Res. Clin. Obstet. Gynaecol. 2018; 51: 1-15.https://dx.doi.org/10.1016/j.bpobgyn.2018.06.001.
  8. Philippa T.K., Andrew А.W. Endometriosis: etiology, pathobiology and therapeutic prospects. Cell. 2021; 184(11): 2807-24.https://dx.doi.org/10.1016/j.cell.2021.04.041.
  9. Endometriosis. Guideline of European Society of Human Reproduction and Embryology. 2022; 112p. Available at: https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Endometriosis-guideline
  10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Gonadotropin Releasing Hormone (GnRH) Analogues. 2018.
  11. Surrey E.S. GnRH Agonists in the treatment of symptomatic endometriosis: a review. F&S Reports. 2022. https://dx.doi.org/10.1016/j.xfre.2022.11.009.
  12. Ceccaroni M., Clarizia R., Liverani S., Donati A., Ceccarello M., Manzone M. et al. Dienogest vs GnRH agonists as postoperative therapy after laparoscopic eradication of deep infiltrating endometriosis with bowel and parametrial surgery: a randomized controlled trial. Gynecol. Endocrinol. 2021; 37(10):930-3. https://dx.doi.org/10.1080/09513590.2021.1929151.
  13. Brown J., Farquhar C. Endometriosis: an overview of cochrane reviews. Cochrane Database Syst. Rev. 2014; (3): CD009590. https://dx.doi.org/10.1002/14651858.CD009590.pub2.
  14. Yang Y., Zhu W., Chen S., Zhang G., Chen M., Zhuang Y. Laparoscopic surgery combined with GnRH agonist in endometriosis. J. Coll. Physicians Surg. Pak. 2019; 29(4): 313-6. https://dx.doi.org/10.29271/jcpsp.2019.04.313.
  15. Sallam H.N., Garcia-Velasco J.A., Dias S., Arici A. Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis. Cochrane Database Syst. Rev. 2006; (1): CD004635.https://dx.doi.org/10.1002/14651858.CD004635.pub2.
  16. Rodríguez-Tárrega E., Monzo A.M., Quiroga R., Polo-Sánchez P., Fernández-Colom P., Monterde-Estrada M. et al. Effect of GnRH agonist before IVF on outcomes in infertile endometriosis patients: a randomized controlled trial. Reprod. Biomed. Online. 2020; 41(4): 653-62. https://dx.doi.org/10.1016/j.rbmo.2020.06.020.
  17. Sauerbrun-Cutler M., Alvero R. Short- and long-term impact of gonadotropin-releasing hormone analogue treatment on bone loss and fracture. Fertil. Steril. 2019; 112(5):799-803. https://dx.doi.org/10.1016/j.fertnstert.2019.09.037.
  18. DiVasta A.D., Feldman H.A., Sadler Gallagher J., Stokes N.A., Laufer M.R., Hornstein M.D. et al. Hormonal add-back therapy for females treated with gonadotropin-releasing hormone agonist for endometriosis: a randomized controlled trial. Obstet. Gynecol. 2015; 126(3): 617-27.https://dx.doi.org/10.1097/AOG.0000000000000964.
  19. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Эндометриоз. M.; 2020. Доступно по: https://cr.minzdrav.gov.ru/recomend/259_1 [Ministry of Health of the Russian Federation. Clinical Guidelines. Endometriosis. Moscow; 2020. Available at:https://cr.minzdrav.gov.ru/recomend/259_1 (in Russian)].
  20. Reis F.M., Coutinho L.M., Vannuccini S., Batteux F., Chapron C., Petraglia F. Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure. Hum. Reprod. Update. 2020; 26(4): 565-85. https://dx.doi.org/10.1093/humupd/dmaa009.
  21. Soares S.R., Martínez-Varea A., Hidalgo-Mora J.J., Pellicer A. Pharmacologic therapies in endometriosis: a systematic review. Fertil. Steril. 2012; 98(3): 529-55. https://dx.doi.org/10.1016/j.fertnstert.2012.07.1120.
  22. Gezer A., Oral E. Progestin therapy in endometriosis. Womens Health (Lond). 2015; 11(5): 643-52. https://dx.doi.org/10.2217/whe.15.42.
  23. Vercellini P., Buggio L., Frattaruolo M.P., Borghi A., Dridi D., Somigliana E. Medical treatment of endometriosis-related pain. Best Pract. Res. Clin. Obstet. Gynaecol. 2018; 51: 68-91. https://dx.doi.org/10.1016/j.bpobgyn.2018.01.015.
  24. Vercellini P., Buggio L., Berlanda N., Barbara G., Somigliana E., Bosari S. Estrogen-progestins and progestins for the management of endometriosis. Fertil. Steril. 2016; 106(7): 1552-71.e2. https://dx.doi.org/10.1016/j.fertnstert.2016.10.022.
  25. Strowitzki T., Faustmann T., Gerlinger C., Schumacher U., Ahlers C., Seitz C. Safety and tolerability of dienogest in endometriosis: pooled analysis from the European clinical study program. Int. J. Womens Health. 2015; 7: 393-401. https://dx.doi.org/10.2147/IJWH.S77202.
  26. Klipping C., Duijkers I., Remmers A., Faustmann T., Zurth C., Klein S. et al. Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmacodynamic trial of healthy women. J. Clin. Pharmacol. 2012; 52(11): 1704-13. https://dx.doi.org/10.1177/0091270011423664.
  27. Petraglia F., Hornung D., Seitz C., Faustmann T., Gerlinger C., Luisi S. et al. Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Arch. Gynecol. Obstet. 2012; 285(1): 167-73.https://dx.doi.org/10.1007/s00404-011-1941-7.
  28. Lee S.R., Yi K.W., Song J.Y., Seo S.K., Lee D.Y., Cho S. et al. Efficacy and safety of long-term use of dienogest in women with ovarian endometrioma. Reprod. Sci. 2018; 25(3): 341-6. https://dx.doi.org/10.1177/1933719117725820.
  29. Vignali M., Belloni G.M., Pietropaolo G., Barbasetti Di Prun A., Barbera V., Angioni S. Effect of dienogest therapy on the size of the endometrioma. Gynecol. Endocrinol. 2020; 36(8): 723-7. https://dx.doi.org/10.1080/09513590.2020.1725965.
  30. Muzii L., Galati G., Di Tucci C., Di Feliciantonio M., Perniola G., Di Donato V. et al. Medical treatment of ovarian endometriomas: a prospective evaluation of the effect of dienogest on ovarian reserve, cyst diameter, and associated pain. Gynecol. Endocrinol. 2020; 36(1): 81-3. https://dx.doi.org/10.1080/09513590.2019.1640199.
  31. Ota Y., Andou M., Yanai S., Nakajima S., Fukuda M., Takano M. et al. Long-term administration of dienogest reduces recurrence after excision of endometrioma. J. Endometriosis. 2015; 7(2): 63 -7. https://dx.doi.org/10.5301/je.5000219.
  32. Papíková Z., Hudeček R., Ventruba P., Szypulová M. Efficacy of dienogest treatment of clinical symptoms of rectovaginal endometriosis. Ceska Gynekol. 2019; 84(5): 331-6.
  33. Vercellini P., Bracco B., Mosconi P., Roberto A., Alberico D., Dhouha D. Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study. Fertil. Steril. 2016; 105(3): 734-43.e3. https://dx.doi.org/10.1016/j.fertnstert.2015.11.016.
  34. Morotti M., Venturini P.L., Biscaldi E., Racca A., Calanni L., Vellone V.G. et al. Efficacy and acceptability of long-term norethindrone acetate for the treatment of rectovaginal endometriosis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2017; 213; 4-10. https://dx.doi.org/10.1016/j.ejogrb.2017.03.033.
  35. Подзолкова Н.М., Татарчук Т.Ф., Дощанова А.М., Ешимбетова Г.З., Сумятина Л.В. Нормализация менструального цикла дидрогестероном. Акушерство и гинекология. 2018; 6: 70-6. [Podzolkova N.M., Tatarchuk T.F., Doshchanova A.M., Eshimbetova G., Sumyatina L.V. Menstrual cycle normalization with dydrogesterone. Obstetrics and Gynecology. 2018; 6: 70-6. (in Russian)]. https://dx.doi.org/10.18565/aig.2018.6.70-76.
  36. Беженарь В.Ф., Круглов С.Ю., Кузьмина Н.С., Крылова Ю.С., Абилбекова А.К., Жемчужина Т.Ю. Целесообразность длительной гормональной терапии эндометриоза после хирургического лечения. Акушерство и гинекология. 2021; 4: 134-42. [Bezhenar V.F., Kruglov S.Yu., Kuzmina N.S., Krylova Yu.S., Sergienko A.S., Abilbekova A.K., Zhemchuzhina T.Yu. Effectiveness of long-term hormone therapy for endometriosis after surgical treatment. Obstetrics and Gynecology. 2021; 4: 134-42. (in Russian)]. https://dx.doi.org/10.18565/aig.2021.4.134-142.
  37. Сухих Г.Т., Адамян Л.В., Дубровина С.О., Козаченко А.В., Баранов И.И., Радзинский В.Е. и др. Дидрогестерон для лечения подтвержденного эндометриоза: ключевые результаты наблюдательного открытого многоцентрового исследования в условиях реальной клинической практики (исследование OРХИДЕЯ). Акушерство и гинекология: новости, мнения, обучение. 2020: 8(4): 79-81. [Sukhikh G.T., Adamyan L.V., Dubrovina S.O., Kozachenko A.V., Baranov I.I., Radzinsky V.E. et al. Didrogesterone for the treatment of confirmed endometriosis: key results of an observational open multicenter study in real clinical practice (ORCHIDE Study). Obstetrics and Gynecology: News, Opinions, Training. 2020: 8(4): 79-81. (in Russian)]. https://dx.doi.org/10.24411/2303-9698-2020-14006.
  38. Kitawaki J., Koga K., Kanzo T., Momoeda M. An assessment of the efficacy and safety of dydrogesterone in women with ovarian endometrioma: an open-label multicenter clinical study. Reprod. Med. Biol. 2021; 20(3): 345-51.https://dx.doi.org/10.1002/rmb2.12391.
  39. Vigano P., Somigliana E., Vercellini P. Levonorgestrel-releasing intrauterine system for the treatment of endometriosis: biological and clinical evidence. Womens Health (Lond). 2007; 3(2): 207-14.https://dx.doi.org/10.2217/17455057.3.2.207.
  40. Yucel N., Baskent E., Karamustafaoglu Balci B., Goynumer G. The levonorgestrel-releasing intrauterine system is associated with a reduction in dysmenorrhoea and dyspareunia, a decrease in CA 125 levels, and an increase in quality of life in women with suspected endometriosis. Aust. N. Z. J. Obstet. Gynaecol. 2018; 58(5): 560-3. https://dx.doi.org/ 10.1111/ajo.12773.
  41. Chen Y.J., Hsu T.F., Huang B.S., Tsai H.W., Chang Y.H., Wang P.H. Postoperative maintenance levonorgestrel-releasing intrauterine system and endometrioma recurrence: a randomized controlled study. Am. J. Obstet. Gynecol. 2017; 216(6): 582-9. https://dx.doi.org/10.1016/j.ajog.2017.02.008.
  42. Ferrero S., Scala C., Ciccarelli S., Vellone V.G., Barra F. Treatment of rectovaginal endometriosis with the etonogestrel-releasing contraceptive implant. Gynecol. Endocrinol. 2020; 36(6): 540-4. https://dx.doi.org/10.1080/09513590.2019.1689552.
  43. Carvalho N., Margatho D., Cursino K., Benetti-Pinto C.L., Bahamondes L. Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial. Fertil. Steril. 2018; 110(6): 1129-36. https://dx.doi.org/10.1016/j.fertnstert.2018.07.003.
  44. Vannuccini S., Clemenza S., Rossi M., Petraglia F. Hormonal treatments for endometriosis: the endocrine background. Rev. Endocr. Metab. Disord. 2022; 23(3): 333-55. https://dx.doi.org/10.1007/s11154-021-09666-w.
  45. Barbara G., Buggio L., Facchin F., Vercellini P. Medical treatment for endometriosis: tolerability, quality of life and adherence. Front. Glob. Womens Health. 2021; 2: 729601. https://dx.doi.org/10.3389/fgwh.2021.729601.
  46. Donnez J., Binda M.M., Donnez O., Dolmans M.M. Oxidative stress in the pelvic cavity and its role in the pathogenesis of endometriosis. Fertil. Steril. 2016; 106(5): 1011-7. https://dx.doi.org/10.1016/j.fertnstert.2016.07.1075.
  47. Vercellini P., DE Matteis S., Somigliana E., Buggio L., Frattaruolo M.P., Fedele L. Long-term adjuvant therapy for the prevention of postoperative endometrioma recurrence: a systematic review and meta-analysis. Acta Obstet. Gynecol. Scand. 2013; 92(1): 8-16. https://dx.doi.org/10.1111/j.1600-0412.2012.01470.x.
  48. Grandi G., Barra F., Ferrero S., Sileo F., Bertucci E., Napolitano A. Hormonal contraception in women with endometriosis: a systematic review. Eur. J. Contracept. Reprod. Health Care. 2019; 24(1): 61-70. https://dx.doi.org/10.1080/13625187.2018.1550576.
  49. Becker C.M., Gattrell W.T., Gude K., Singh S.S. Reevaluating response and failure of medical treatment of endometriosis: a systematic review. Fertil. Steril. 2017; 108(1): 125-36. https://dx.doi.org/10.1016/j.fertnstert.2017.05.004.
  50. Casper R.F. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil. Steril. 2017; 107(3): 533-6. https://dx.doi.org/10.1016/j.fertnstert.2017.01.003.
  51. Harada T., Kosaka S., Elliesen J., Yasuda M., Ito M., Momoeda M. Ethinylestradiol 20 mg/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain: a randomized controlled trial. Fertil. Steril. 2017; 108(5): 798-805. https://dx.doi.org/10.1016/j.fertnstert.2017.07.1165.
  52. Clemenza S., Sorbi F., Noci I., Capezzuoli T., Turrini I., Carriero C. et al. From pathogenesis to clinical practice: emerging medical treatments for endometriosis. Best Pract. Res. Clin. Obstet. Gynaecol. 2018; 51: 92-101. https://dx.doi.org/10.1016/j.bpobgyn.2018.01.021.
  53. Donnez J., Taylor R.N., Taylor H.S. Partial suppression of estradiol: a new strategy in endometriosis management? Fertil. Steril. 2017; 107(3): 568-70. https://dx.doi.org/10.1016/j.fertnstert.2017.01.013.
  54. Taylor H.S., Giudice L.C., Lessey B.A., Abrao M.S., Kotarski J., Archer D.F. et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N. Engl. J. Med. 2017; 377(1): 28-40. https://dx.doi.org/10.1056/NEJMoa1700089.
  55. Surrey E., Taylor H.S., Giudice L., Lessey B.A., Abrao M.S., Archer D.F. et al. long-term outcomes of elagolix in women with endometriosis: results from two extension studies. Obstet. Gynecol. 2018; 132(1): 147-60.https://dx.doi.org/10.1097/AOG.0000000000002675.
  56. Ng J., Chwalisz K., Carter D.C., Klein C.E. Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women. J. Clin. Endocrinol. Metab. 2017; 102(5): 1683-91.https://dx.doi.org/10.1210/jc.2016-3845.
  57. Leyland N., Estes S.J., Lessey B.A., Advincula A.P., Taylor H.S. A Clinician's guide to the treatment of endometriosis with eagolix. J. Womens Health (Larchmt). 2021; 30(4): 569-78. https://dx.doi.org/10.1089/jwh.2019.8096.
  58. Osuga Y., Seki Y., Tanimoto M., Kusumoto T., Kudou K., Terakawa N. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study. Fertil. Steril. 2021; 115(2): 397-405. https://dx.doi.org/10.1016/j.fertnstert.2020.07.055.
  59. Pernicova I., Korbonits M. Metformin--mode of action and clinical implications for diabetes and cancer. Nat. Rev. Endocrinol. 2014; 10(3): 143-56.https://dx.doi.org/10.1038/nrendo.2013.256.
  60. Zhou Y., Xu J.N., Zeng C., Li X., Zhou Y.F., Qi Y. Metformin suppresses prostaglandin E2-induced cytochrome P450 aromatase gene expression and activity via stimulation of AMP-activated protein kinase in human endometriotic stromal cells. Reprod. Sci. 2015; 22(9): 1162-70.https://dx.doi.org/10.1177/1933719115590664.
  61. Jamali N., Zal F., Mostafavi-Pour Z., Samare-Najaf M., Poordast T., Dehghanian A. Ameliorative effects of quercetin and metformin and their combination against experimental endometriosis in rats. Reprod. Sci. 2021; 28(3): 683-92. https://dx.doi.org/10.1007/s43032-020-00377-2.
  62. Stochino-Loi E., Major A., Gillon T., Ayoubi J., Feki A., Bouquet de Joliniere J. Metformin, the rise of a new medical therapy for endometriosis? A systematic review of the literature. Front. Med. (Lausanne). 2021; 8: 581311.https://dx.doi.org/10.3389/fmed.2021.581311.
  63. Mikus M., Vitale S.G., Coric M., Zajec V., Ciebiera M., Carugno J. et al. State of the art, new treatment strategies, and emerging drugs for non-hormonal treatment of endometriosis: a systematic review of randomized control trials. Gynecol. Endocrinol. 2022 Oct 13: 1-7. https://dx.doi.org/10.1080/09513590.2022.2133105.
  64. Ekici E., Guney M., Naziroglu M. Protective effect of cabergoline on mitochondrial oxidative stress-induced apoptosis is mediated by modulations of TRPM2 in neutrophils of patients with endometriosis. J. Bioenerg. Biomembr. 2020; 52(3): 131-42. https://dx.doi.org/10.1007/s10863-020-09830-y.
  65. Kim Y.S., Kim Y.J., Kim M.J., Lee S.J., Kwon H., Lee J.H. Novel medicine for endometriosis and its therapeutic effect in a mouse model. Biomedicines. 2020; 8(12): 619. https://dx.doi.org/10.3390/biomedicines8120619.
  66. Ercan C.M., Kayaalp O., Cengiz M., Keskin U., Yumusak N., Aydogan U. et al. Comparison of efficacy of bromocriptine and cabergoline to GnRH agonist in a rat endometriosis model. Arch. Gynecol. Obstet. 2015; 291(5): 1103-11.https://dx.doi.org/10.1007/s00404-014-3524-x.
  67. Akyol A., Kavak E., Akyol H., Pala S., Gursu F. The non-ergot derived dopamine agonist quinagolide as an anti-endometriotic agent. Gynecol. Obstet. Invest. 2017; 82(6): 527-32. https://dx.doi.org/10.1159/000452796.
  68. Yarmolinskaya M., Suslova E., Tkachenko N., Molotkov A., Kogan I. Dopamine agonists as genital endometriosis target therapy. Gynecol. Endocrinol. 2020; 36 (Suppl. 1): 7-11. https://dx.doi.org/10.1080 / 09513590.2020.1816720.

Received 07.12.2022

Accepted 20.12.2022

About the Authors

Madina R. Dumanovskaya, PhD, Researcher, Gynecological Endocrinology Department, Academician V.I. Kulakov NMRC for OG&P, Ministry of Health of Russia,
m_dumanovskaya@oparina4.ru, https://orcid.org/0000-0001-7286-6047, 117997, Russia, Moscow, Oparina str., 4.
Guzal I. Tabeeva, PhD, Senior Researcher, Gynecological Endocrinology Department, Academician V.I. Kulakov NMRC for OG&P, Ministry of Health of Russia,
g_tabeeva@oparina4.ru, https://orcid.org/0000-0003-1498-6520, 117997, Russia, Moscow, Oparina str., 4.
Julia A. Ivannikova, physician, resident, I.M. Sechenov First MSMU, Ministry of Health of Russia (Sechenov University), ivannikova0@yandex.ru, 119991, Russia, Moscow, Trubetskaya str., 8-2
Alina E. Solopova, Dr. Med. Sci., Associate Professor, Leading Researcher, Department of Radiology, Academician V.I. Kulakov NMRC for OG&P, Ministry of Health of Russia, a_solopova@oparina4.ru, https://orcid.org/0000-0003-4768-115X, 117997, Russia, Moscow, Academician Oparin str., 4.
Aleksandra V. Asaturova, Dr. Med. Sci., Head of 1st Pathology Department, Academician V.I. Kulakov NMRC for OG&P, Ministry of Health of Russia,
a_asaturova@oparina4.ru, https://orcid.org/0000-0001-8739-5209, 117997, Russia, Moscow, Oparina str., 4.
Antonina A. Smetnik, PhD, Head of the Department of Gynecological Endocrinology, Academician V.I. Kulakov NMRC for OG&P, Ministry of Health of Russia,
a_smetnik@oparina4.ru, https://orcid.org/0000-0002-0627-3902, 117997, Russia, Moscow, Academician Oparin str., 4.
Patimat M. Alieva, obstetrician-gynecologist, postgraduate student at the Department of Gynecological Endocrinology, Academician V.I. Kulakov NMRC for OG&P,
Ministry of Health of Russia, patimat.alieva.1997@bk.ru, 117997, Russia, Moscow, Academician Oparin str., 4.
Elena I. Ermakova, PhD, Senior Researcher at the Department of Gynecological Endocrinology, Academician V.I. Kulakov NMRC for OG&P, Ministry of Health of Russia, e_ermakova@oparina4.ru, https://orcid.org/0000-0002-6629-051X, 117997, Russia, Moscow, Academician Oparin str., 4.
Stanislav V. Pavlovich, Ph.D., Academic Secretary, Academician V.I. Kulakov NMRC for OG&P, Ministry of Health of Russia,
117997, Russia, Moscow, Academician Oparin str., 4; Professor, Department of Obstetrics, Gynecology, Perinatology and Reproductology, I.M. Sechenov First MSMU,
Ministry of Health of Russia (Sechenov University), 119991, Russia, Moscow, Trubetskaya str., 8-2, s_pavlovich@oparina4.ru, https://orcid.org/0000-0002-1313-7079,
Corresponding author: Madina R. Dumanovskaya, m_dumanovskaya@oparina4.ru

Similar Articles

By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.